株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

マイクロバイオーム治療薬の世界市場の分析

Global Market Study on Microbiome Therapeutics: United States Projected to be the Dominant Regional Market During 2018 - 2025

発行 Persistence Market Research 商品コード 612884
出版日 ページ情報 英文 144 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
マイクロバイオーム治療薬の世界市場の分析 Global Market Study on Microbiome Therapeutics: United States Projected to be the Dominant Regional Market During 2018 - 2025
出版日: 2018年01月30日 ページ情報: 英文 144 Pages
概要

当レポートでは、世界のマイクロバイオーム治療薬の市場について分析し、製品の概要や市場の構造、主な市場促進・抑制要因、症状別・地域別の市場動向見通し (今後8年間分)、将来の市場機会の規模、市場競争状態、主要企業のプロファイルなどを調査しております。

第1章 エグゼクティブ・サマリー

第2章 市場概略

第3章 市場の観点

  • 市場のダイナミクス
    • マクロ経済要因
    • 市場促進要因
    • 市場抑制要因
    • 市場の傾向

第4章 ベンチャーキャピタルからの資金調達

第5章 パイプライン分析

第6章 マイクロバイオーム治療薬の世界市場:市場機会の評価 (今後8年間分)

  • 市場機会の評価と分析 (単位:米ドル):症状別
    • 2型糖尿病
      • 米国・欧州・日本など
    • クロストリジウム・ディフィシル (C. difficile) 感染症
    • 再発性クロストリジウム・ディフィシル感染症
    • 肥満症
    • 原発性高シュウ酸尿症

第7章 世界のマイクロバイオーム治療薬の潜在性市場

  • クロストリジウム・ディフィシル感染症治療向けの潜在的市場
  • 早産・婦人病向け潜在的市場
  • 糖尿病向け潜在的市場
  • 肥満症向け潜在的市場

第8章 競争環境

  • 企業プロファイル (概要、パイプライン製品、戦略、近年の動向)
    • Microbiome Therapeutics Inc.
    • SERES Therapeutics Inc.
    • LNC Therapeutics Inc.
    • Vedanta Biosciences Inc.
    • Enterome SA
    • Ferring B.V.
    • ViThera Pharmaceuticals Inc.
    • Second Genome Therapeutics
    • Rebiotix
    • Synlogic Inc.
    • 4D Pharma Plc.
    • Ritter Pharmaceuticals
    • AvidBiotics
    • Osel Inc.
    • OxThera AB
    • Evelo Biosciences
    • AOBiome LLC
    • Immuron Ltd.

第9章 前提条件、略語一覧

第10章 分析手法

目次

This Persistence Market Research (PMR) report examines the global microbiome therapeutics market for the period 2018-2025. The primary objective of the report is to offer insights into market opportunity for microbiome therapeutics and pipeline developments in microbiome therapeutics market. The microbiome industry is at an early stage but is undergoing rapid developments in last five years. Particular microbiome therapeutics based on human intestinal microbiome are popular and numerous programs are being carried out to evaluate their therapeutic efficacy in treating or preventing gastrointestinal disorders such as C. difficile infection, ulcerative colitis, inflammatory bowel disease (IBD) etc. among others. The market for microbiome therapeutics is primarily driven by government initiatives in funding microbiome research, success of human microbiome project, need for reliable therapeutics for certain disease indications and huge pipeline of novel microbiome therapeutics.

A highly organized report for gaining maximum clarity

The report analyzes the global opportunity for microbiome based therapeutics in terms of value (US$ Mn) and forecast. The report begins with the market definition and explaining different disease indications for which microbiome therapeutics are being developed. The market view point section includes analysis of Persistence Market Research on key trends, drivers, restraints, and macro factors influencing global market. Opportunity analysis and recommendations section provided in the report allows to better equip clients with crystal clear decision making insights.

Section on venture capital provides the analysis of financing activities by venture partners in microbiome therapeutics in last 6-7 years. The section gives detailed description of venture financing along with the capital raised by various players in microbiome therapeutics market from 2011-2017. The section helps readers to gain insights into the source of financing for novel microbiome therapeutics, most of which are being developed by early stage of clinical stage biotechnology companies.

The next section of the report covers pipeline analysis of microbiome therapeutics. Pipeline analysis section provides analysis by development stage, disease indication, number of active clinical programs by therapeutic area, geographical distribution of clinical trials and analysis by product type. The section helps readers to identify potential competitors that are working on microbiome based drugs for the same therapeutic area. The section gives detailed description of over 120 clinical, preclinical and discovery programs.

The next section of the report highlights global microbiome therapeutics market potential by various indications including C. difficile infection, preterm birth & gynaecology conditions, type 2 diabetes and obesity. The section provides analysis on the bases of epidemiology and potential patient population for each of the indication mentioned and potential for microbiome therapeutics in the global market compared to currently available treatment drugs/products for each of the indication. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global microbiome therapeutics market.

Competitive landscape section is devoted to studying the competition in this novel market

In next section of the report on microbiome therapeutics market, a detailed competitive landscape is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Detailed company profiles include company-specific long-term and short-term strategies, pipeline products in microbiome therapeutics, recent developments, company's microbiome activity analysis (in terms of pipeline, disease areas, industry sectors, number of licensing activities, partnerships, acquisitions and venture capital raised since 2010).

  • Market Taxonomy
  • By Indication
  • Type 2 Diabetes
  • Obesity
  • difficile infection
  • Primary Hyperoxyurea
  • By Region
  • U.S.
  • Europe
  • Japan
  • RoW

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy
  • 2.3. Microbiome Therapeutics Market Overview

3. Market View Point

  • 3.1. Market Dynamics
    • 3.1.1. Macro-Economic Factors
    • 3.1.2. Drivers
    • 3.1.3. Restraints
    • 3.1.4. Trends

4. Venture Capital Financing

5. Pipeline Analysis

6. Global Microbiome Therapeutics Market Opportunity Assessment 2018-2025

  • 6.1. Market Opportunity Assessment (US$ Mn) and Analysis By Indication
    • 6.1.1. Type 2 Diabetes
      • 6.1.1.1. U.S.
      • 6.1.1.2. Europe
      • 6.1.1.3. Japan
      • 6.1.1.4. RoW
    • 6.1.2. C. difficile infection
      • 6.1.2.1. C. difficile Infection
        • 6.1.2.1.1. U.S.
        • 6.1.2.1.2. Europe
        • 6.1.2.1.3. Japan
        • 6.1.2.1.4. RoW
      • 6.1.2.2. Recurrent C. difficile Infection
        • 6.1.2.2.1. U.S.
        • 6.1.2.2.2. Europe
        • 6.1.2.2.3. Japan
        • 6.1.2.2.4. RoW
    • 6.1.3. Obesity
    • 6.1.4. Primary Hyperoxyurea

7. Global Microbiome Therapeutics Market Potential

  • 7.1. Microbiome Therapeutics Market Potential for C. difficile Infection Treatment
  • 7.2. Microbiome Therapeutics Market Potential for Preterm Birth and Gynecology Conditions
  • 7.3. Microbiome Therapeutics Market Potential for Diabetes
  • 7.4. Microbiome Therapeutics Market Potential for Obesity

8. Competition Landscape

  • 8.1. Company Profiles (Details - Overview, pipeline, Strategy, Recent Developments)
    • 8.1.1. Microbiome Therapeutics Inc.
    • 8.1.2. SERES Therapeutics Inc.
    • 8.1.3. LNC Therapeutics Inc.
    • 8.1.4. Vedanta Biosciences Inc.
    • 8.1.5. Enterome SA
    • 8.1.6. Ferring B.V.
    • 8.1.7. ViThera Pharmaceuticals Inc.
    • 8.1.8. Second Genome Therapeutics
    • 8.1.9. Rebiotix
    • 8.1.10. Synlogic Inc.
    • 8.1.11. 4D Pharma Plc.
    • 8.1.12. Ritter Pharmaceuticals
    • 8.1.13. AvidBiotics
    • 8.1.14. Osel Inc.
    • 8.1.15. OxThera AB
    • 8.1.16. Evelo Biosciences
    • 8.1.17. AOBiome LLC
    • 8.1.18. Immuron Ltd.

9. Assumptions and Acronyms Used

10. Research Methodology

List of Table:

  • Table 01: Activities in Microbiome Research Across the Globe (1/2)
  • Table 02: Activities in Microbiome Research Across the Globe (2/2)
  • Table 03: Global Microbiome Therapeutics Market Partnership and Collaborations (1/6)
  • Table 04: Global Microbiome Therapeutics Market Partnership and Collaborations (2/6)
  • Table 05: Global Microbiome Therapeutics Market Partnership and Collaborations (3/6)
  • Table 06: Global Microbiome Therapeutics Market Partnership and Collaborations (4/6)
  • Table 07: Global Microbiome Therapeutics Market Partnership and Collaborations (5/6)
  • Table 08: Global Microbiome Therapeutics Market Partnership and Collaborations (6/6)
  • Table 09: Venture Capital Investments in Microbiome Therapeutics (2017)
  • Table 10: Venture Capital Investments in Microbiome Therapeutics (2016) (1/3)
  • Table 11: Venture Capital Investments in Microbiome Therapeutics (2016) (2/3)
  • Table 12: Venture Capital Investments in Microbiome Therapeutics (2016) (3/3)
  • Table 13: Venture Capital Investments in Microbiome Therapeutics (2015) (2/3)
  • Table 14: Venture Capital Investments in Microbiome Therapeutics (2014)
  • Table 15: Venture Capital Investments in Microbiome Therapeutics (2013)
  • Table 16: Venture Capital Investments in Microbiome Therapeutics (2011-2012)
  • Table 17: Microbiome Therapeutics Pipeline Analysis (1/11)
  • Table 18: Microbiome Therapeutics Pipeline Analysis (2/11)
  • Table 19: Microbiome Therapeutics Pipeline Analysis (3/11)
  • Table 20: Microbiome Therapeutics Pipeline Analysis (4/11)
  • Table 21: Microbiome Therapeutics Pipeline Analysis (5/11)
  • Table 22: Microbiome Therapeutics Pipeline Analysis (6/11)
  • Table 23: Microbiome Therapeutics Pipeline Analysis (7/11)
  • Table 24: Microbiome Therapeutics Pipeline Analysis (8/11)
  • Table 25: Microbiome Therapeutics Pipeline Analysis (9/11)
  • Table 26: Microbiome Therapeutics Pipeline Analysis (10/11)
  • Table 27: Microbiome Therapeutics Pipeline Analysis (11/11)
  • Table 28: Global Microbiome Therapeutics Market Opportunity Assessment, By Type 2 Diabetes Indication, 2018-2025
  • Table 29: Global Microbiome Therapeutics Market Opportunity Assessment, C. difficile Infection, 2018-2025
  • Table 30: Global Microbiome Therapeutics Market Opportunity Assessment, By ObesityIndication, 2018-2025
  • Table 31: Global Microbiome Therapeutics Market Opportunity Assessment, By Obesity Indication, 2018-2025
  • Table 32: Research Programs in the Field Microbiome in Preterm/Premature Birth (1/2)
  • Table 33: Research Programs in the Field of Microbiome in Preterm/Premature Birth (2/2)
  • Table 34: Seres Therapeutics Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 35: Vedanta Biosciences Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 36: Second Genome Therapeutics Microbiome Therapeutics Pipeline Analysis
  • Table 37: Rebiotix, Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 38: Synlogic, Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 39: 4D Pharma PLC. Microbiome Therapeutics Pipeline Analysis
  • Table 40: OxThera AB. Microbiome Therapeutics Pipeline Analysis
  • Table 41: Immuron Ltd IMC. Microbiome Therapeutics Pipeline Analysis
  • Table 42: Enterome Bioscience SA. Microbiome Therapeutics Pipeline Analysis
  • Table 43: Evelo Biosciences Inc., Microbiome Therapeutics Pipeline Analysis
  • Table 44: MicroBiome Therapeutics LLC., Microbiome Therapeutics Pipeline Analysis
  • Table 45: LNC Therapeutics, SA. Microbiome Therapeutics Pipeline Analysis
  • Table 46: Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 47: Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 48: Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 49: Osel Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 50: Ritter Pharmaceuticals Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 51: AOBiome Microbiome Therapeutics Pipeline Analysis

List of Figure:

  • Figure 01: Global Microbiome Therapeutics Market Opportunity By Indication (2025)
  • Figure 02: Number of Partnerships and Collaboration Deals in Microbiome Therapeutics Market (2010 - 2017)
  • Figure 03: Partnerships and Collaborations Among Microbiome Industry
  • Figure 04: Trends in Venture Capital Investments in Microbiome Therapeutics (2011 - 2017)
  • Figure 05: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, by Indication
  • Figure 06: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, By Phase
  • Figure 07: Geographical Distribution of Clinical Trials for Microbiome
  • Figure 08: Distribution of Microbiome Clinical Trials, By Drug Type
  • Figure 09: Number Microbiome Therapeutics Drug Pipeline Projects By Indication (September 2017)
  • Figure 10: Global Microbiome Therapeutics Market Value (US$ Mn) Opportunity Assessment 2018-2025
  • Figure 11: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity Assessment (2018-2025)
  • Figure 12: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 13: Global C. difficile Infection Microbiome Therapeutics Market Opportunity Assessment (2018-2025)
  • Figure 14: Global C. difficile Infection Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 15: Global Obesity Microbiome Therapeutics Market Opportunity Assessment (2018-2025)
  • Figure 16: Global Obesity Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 17: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity Assessment (2018-2025)
  • Figure 18: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 19: Global CDI Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 20: Incidence of C. difficile Infection Across Major Countries as Percentage of Total Hospital Admissions (2016)
  • Figure 21: Composition of Microbiome of Reproductive Organs
  • Figure 22: Number of People(Mn) with Diabetes, By Region (2015 & 2040)
  • Figure 23: Global Diabetes Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 24: Top Ten Countries/Territories For Diabetes Related Health Expenditure (2015)
  • Figure 25: Global Obesity Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 26: Number of people (Mn) with Obesity (2016 & 2020)
  • Figure 27: Seres Therapeutics Inc. Microbiome Activity Analysis
  • Figure 28: Vedanta Biosciences Microbiome Activity Analysis
  • Figure 29: Second Genome Inc. Microbiome Activity Analysis
  • Figure 30: Second Genome Therapeutics Pipeline Active and Inactive Programs By Indication
  • Figure 31: Rebiotix Inc. Microbiome Activity Analysis
  • Figure 32: Synlogic Inc. Microbiome Activity Analysis
  • Figure 33: 4D pharma PLC. Microbiome Activity Analysis
  • Figure 34: OxThera AB Microbiome Activity Analysis
  • Figure 35: OxThera AB Pipeline Programs By Phase
  • Figure 36: Immuron Ltd. Microbiome Activity Analysis
  • Figure 37: Enterome Biosciences SA Microbiome Activity Analysis
  • Figure 38: Evelo Biosciences Inc. Microbiome Activity Analysis
  • Figure 39: Evelo Biosciences Inc. Pipeline Active and Inactive Programs By Indication
  • Figure 40: Microbiome Therapeutics Inc. Activity Analysis
  • Figure 41: Microbiome Therapeutics Inc. Pipeline, Active and Inactive Programs By Indication
  • Figure 42: Ferring B.V. Microbiome Activity Analysis
  • Figure 43: ViThera Pharmaceuticals, Inc. Microbiome Activity Analysis
  • Figure 44: C3J Therapeutics, Inc. Microbiome Activity Analysis
  • Figure 45: C3J Therapeutics Inc. Pipeline Active and Inactive Programs By Indication
  • Figure 46: Second Genome Inc. Microbiome Activity Analysis
  • Figure 47: Osel Pipeline Active and Inactive Programs By Indication
  • Figure 48: Second Genome Inc. Microbiome Activity Analysis
  • Figure 49: Second Genome Inc. Microbiome Activity Analysis
  • Figure 50: AOBiome Clinical Pipeline Programs By Indication